Cabaletta Bio (CABA) CCO Steve Gavel purchases 22,170 shares in open market

Rhea-AI Filing Summary

Cabaletta Bio, Inc. insider trade: Chief Commercial Officer Steve Gavel reported purchasing 22,170 shares of Cabaletta Bio common stock on January 21, 2026. The Form 4 shows this as an open-market buy coded "P" at a weighted average price of $2.265 per share.

According to the filing, the shares were acquired in multiple trades at prices ranging from $2.26 to $2.27 per share, and Gavel beneficially owns 22,170 common shares following this transaction, held directly. The insider also notes a commitment to make detailed trade price information available to the company, its security holders, or the SEC staff upon request.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gavel Steve

(Last) (First) (Middle)

C/O CABALETTA BIO, INC.

2929 ARCH STREET, SUITE 600

(Street)

PHILADELPHIA PA 19104

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cabaletta Bio, Inc. [ CABA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/21/2026		P		22,170	A	$2.265(1)	22,170	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased at prices ranging from $2.26 to $2.27, inclusive. The reporting person has provided to the Issuer, and undertakes to provide any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

	By: /s/ Michael Gerard, as Attorney-in-Fact	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Cabaletta Bio (CABA) report in this Form 4?

The filing reports that Chief Commercial Officer Steve Gavel purchased 22,170 shares of Cabaletta Bio common stock in an open-market transaction on January 21, 2026.

At what price did Steve Gavel buy Cabaletta Bio (CABA) shares?

The Form 4 lists a weighted average purchase price of $2.265 per share, with individual trades executed in a range from $2.26 to $2.27 per share.

How many Cabaletta Bio (CABA) shares does Steve Gavel own after this transaction?

Following the reported transaction, Steve Gavel beneficially owns 22,170 shares of Cabaletta Bio common stock, held in direct ownership.

Was this Cabaletta Bio (CABA) insider trade made under Rule 10b5-1?

The form includes a checkbox for indicating transactions under a Rule 10b5-1 plan, but the provided content does not show that this box was marked for the reported trade.

Who is the reporting person in this Cabaletta Bio (CABA) Form 4 filing?

The reporting person is Steve Gavel, who serves as Chief Commercial Officer of Cabaletta Bio, Inc. and is not listed as a director or 10% owner in this filing.

What additional pricing details does the Cabaletta Bio (CABA) Form 4 footnote provide?

The footnote explains that the reported price is a weighted average and that the $2.26–$2.27 per share trade breakdown is available from the reporting person to the issuer, any security holder, or SEC staff upon request.